Public Market Listing
1801 HKEX
HKEX primary exchange listing
External market data link · No third-party exchange redistribution
Assets (18 total) 18 Total Assets
4 Approved
9 Phase 3 / Filed
5 Phase 1–2 / Early
14 Diseases
Disease: All diseases (18) Non-Small Cell Lung Cancer (8) Acute Myeloid Leukemia (2) Multiple Myeloma (2) Colorectal Cancer (2) Obesity (2) Biliary Tract Cancer (1) Solid Tumors (1) Type 2 Diabetes (1) Chronic Myeloid Leukemia (1) Inflammatory Bowel Disease (1) Psoriasis (1) Atherosclerotic Cardiovascular Disease (1) Hypertension (1) Atopic Dermatitis (1)
Stage: All stages (18) Approved / Phase 4 (4) Phase 3 / Filed (9) Phase 2 Phase 1 / Preclinical
Quick filter: All (18) Non-Small Cell Lung Cancer (8) Acute Myeloid Leukemia (2) Multiple Myeloma (2) Colorectal Cancer (2) Obesity (2)
Showing 18 of 18 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Approved FGFR1/2/3 Small molecule
Non-Small Cell Lung Cancer Biliary Tract Cancer
Cholangiocarcinoma Approved FLT3 Small molecule
Approved RET Small molecule
Non-Small Cell Lung Cancer Solid Tumors
Approved ROS1 Small molecule
Non-Small Cell Lung Cancer
ROS1-Positive Non-Small Cell Lung Cancer Phase 3 GPRC5D x BCMA x CD3 Multispecific antibody
Phase 3 VEGF-A Monoclonal antibody
Non-Small Cell Lung Cancer Colorectal Cancer
Phase 3 PD-1 x IL-2Rα (IL2RA) Multispecific antibody
Non-Small Cell Lung Cancer Colorectal Cancer
Phase 3 EGFR · EGFR T790M (resistant mutant, selective over wild-type EGFR) Small molecule
Non-Small Cell Lung Cancer
Phase 3 GLP-1/glucagon receptor (dual) Peptide
Phase 3 BCR-ABL (also AKT, c-Kit, ERK) Small molecule
Acute Myeloid Leukemia Chronic Myeloid Leukemia
Chronic Myeloid Leukemia with T315I Mutation Phase 3 IL-23 p19 Monoclonal antibody
Inflammatory Bowel Disease Psoriasis
Ulcerative Colitis Phase 3 PD-1 Monoclonal antibody
Non-Small Cell Lung Cancer
Phase 3 PCSK9 Monoclonal antibody
Atherosclerotic Cardiovascular Disease
Phase 2 KRAS G12C Small molecule
Non-Small Cell Lung Cancer
Phase 2 Angiotensinogen (AGT) RNA / oligonucleotide
Show all 18 assets (3 more) ↓ Discontinued programmes (1) Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events (32 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (5) November 2026 (1) IBI363 Phase 2 Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer Est. primary completion 2026-11-30 ·
NCT07122687 ·
CT.gov ↗ What to watch
December 2026 (4) Est. primary completion 2026-12-31 ·
NCT06797297 ·
CT.gov ↗ What to watch
IBI363 Phase 2 Resectable Stage II-III Non-small Cell Lung Cancer Est. primary completion 2026-12-31 ·
NCT07402070 ·
CT.gov ↗ What to watch
IBI3003 Phase 2 Multiple Myeloma Est. primary completion 2026-12-31 ·
NCT07764861 ·
CT.gov ↗ What to watch
mazdutide Phase 3 Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) Est. primary completion 2026-12-31 ·
NCT06884293 ·
CT.gov ↗ What to watch
2027 (11) March 2027 (1) Est. primary completion 2027-03-31 ·
NCT06640361 ·
CT.gov ↗ What to watch
May 2027 (2) Quizartinib Phase 1/2 Acute Myeloid Leukemia Est. primary completion 2027-05-01 ·
NCT03793478 ·
CT.gov ↗ What to watch
mazdutide Phase 3 Sleep Apnea, Obstructive, Obesity Est. primary completion 2027-05-07 ·
NCT06931028 ·
CT.gov ↗ What to watch
June 2027 (2) Olverembatinib Phase 3 Chronic Myeloid Leukemia, CML, CML, Chronic Phase Est. primary completion 2027-06-30 ·
NCT06423911 ·
CT.gov ↗ What to watch
September 2027 (2) mazdutide Phase 2 Obesity, Overweight Est. primary completion 2027-09 ·
NCT06143956 ·
CT.gov ↗ What to watch
Pegenzileukin Phase 1/2 Plasma Cell Myeloma Refractory Est. primary completion 2027-09-13 ·
NCT04643002 ·
CT.gov ↗ What to watch
October 2027 (2) mazdutide Phase 3 Adolescents With Obesity or Overweight With Weight-Related Comorbidities Est. primary completion 2027-10-31 ·
NCT07255209 ·
CT.gov ↗ What to watch
Limertinib Phase 3 Locally Advanced or Metastatic NSCLC Est. primary completion 2027-10-31 ·
NCT07109531 ·
CT.gov ↗ What to watch
December 2027 (2) Sintilimab Phase 2/3 Hepatocellular Carcinoma (HCC) Est. primary completion 2027-12-31 ·
NCT07490262 ·
CT.gov ↗ What to watch
Olverembatinib Phase 3 Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive Est. primary completion 2027-12-31 ·
NCT06051409 ·
CT.gov ↗ What to watch
2028 (5) June 2028 (1) Quizartinib Phase 2 Acute Myeloid Leukemia, Leukemia Est. primary completion 2028-06-06 ·
NCT06824168 ·
CT.gov ↗ What to watch
September 2028 (1) Olverembatinib Phase 1/2 Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy Est. primary completion 2028-09 ·
NCT04501120 ·
CT.gov ↗ What to watch
October 2028 (2) Est. primary completion 2028-10-19 ·
NCT06081920 ·
CT.gov ↗ What to watch
IBI363 Phase 3 Colorectal Cancer Est. primary completion 2028-10-31 ·
NCT07722494 ·
CT.gov ↗ What to watch
November 2028 (1) IBI363 Phase 3 IO Resistant Squamous and Nonsquamous NSCLC Est. primary completion 2028-11-01 ·
NCT07217301 ·
CT.gov ↗ What to watch
2029 (4) January 2029 (1) Taletrectinib Phase 3 Non Small Cell Lung Cancer Est. primary completion 2029-01 ·
NCT06564324 ·
CT.gov ↗ What to watch
March 2029 (1) IBI3016 Phase 2 Hypertension Est. primary completion 2029-03-27 ·
NCT07352969 ·
CT.gov ↗ What to watch
May 2029 (1) IBI3003 Phase 3 Relapsed or Refractory Multiple Myeloma Est. primary completion 2029-05-31 ·
NCT07623798 ·
CT.gov ↗ What to watch
December 2029 (1) picankibart Phase 2/3 Psoriatic Arthritis Est. primary completion 2029-12-31 ·
NCT07295509 ·
CT.gov ↗ What to watch
2030 (5) March 2030 (1) Sintilimab Phase 3 Locally Advanced Rectal Cancer Est. primary completion 2030-03-25 ·
NCT07917468 ·
CT.gov ↗ What to watch
June 2030 (2) Quizartinib Phase 3 Leukemia Est. primary completion 2030-06-26 ·
NCT06578247 ·
CT.gov ↗ What to watch
Sintilimab Phase 2 CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Est. primary completion 2030-06-30 ·
NCT07483567 ·
CT.gov ↗ What to watch
August 2030 (1) Taletrectinib Phase 3 Non-small Cell Lung Cancer (NSCLC) Est. primary completion 2030-08-30 ·
NCT07154706 ·
CT.gov ↗ What to watch
December 2030 (1) Limertinib Phase 3 EGFR Activating Mutation, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), MET Positive Est. primary completion 2030-12-30 ·
NCT07897188 ·
CT.gov ↗ What to watch
2031 (2) February 2031 (1) Pemigatinib · Pemazyre Phase 2 Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma Est. primary completion 2031-02-25 ·
NCT07862998 ·
CT.gov ↗ What to watch
December 2031 (1) Sintilimab Phase 2/3 Resectable Gastric/Gastroesophageal Junction Adenocarcinoma Est. primary completion 2031-12-31 ·
NCT07643623 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (14) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
4 January 2027 FDA action date Taletrectinib FDA target action date for IBTROZI sNDA Recent
9 November 2026 Topline result Tafolecimab CREDIT-5 Phase 3 meets its primary endpoint 16 September 2026 Approval Taletrectinib FDA approves IBTROZI supplemental application with updated duration of response 29 June 2026 Filing accepted Taletrectinib UK MHRA validates taletrectinib MAA June 2026 Filing accepted Taletrectinib MHRA validates taletrectinib marketing authorisation application UK, MHRA · Nuvation Bio Inc. and Eisai ·
Source ↗ 6 May 2026 Filing accepted Taletrectinib FDA accepts sNDA for IBTROZI with updated duration of response data March 2026 Filing accepted Taletrectinib EMA validates taletrectinib marketing authorisation application EU, EMA · Nuvation Bio Inc. and Eisai ·
Source ↗ 25 November 2025 Filing accepted mazdutide NMPA CDE accepts the mazdutide 9 mg supplementary application for review CN, NMPA · Innovent Biologics ·
Source ↗ 19 November 2025 Topline result mazdutide GLORY-2 (NCT06164873) Phase 3 of mazdutide 9 mg met its primary and all key secondary endpoints 26 October 2025 Topline result mazdutide DREAMS-3 (NCT06184568) Phase 3 head-to-head versus semaglutide met its primary endpoint 27 June 2025 Approval mazdutide NMPA approves mazdutide for chronic weight management 5 June 2025 Filing accepted Sintilimab NMPA accepts the NDA for sintilimab plus fruquintinib in renal cell carcinoma CN, NMPA · HUTCHMED and Innovent Biologics ·
Source ↗ 19 March 2025 Topline result Sintilimab FRUSICA-2 Phase II/III of fruquintinib plus sintilimab meets primary endpoint The 12 most recent of 13 past events are shown.
Financial reports Quarterly & interim (5)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-H1 $821M $139M $1.5B — report ↗
Innovent Biologics reported revenue of $821.43M, up 49.5% YoY, R&D spend of $139.2M, down 28.4% YoY, and cash and equivalents of $1,536.05M for H1 2025.
Figures only: this period's report disclosed no narrative text
View 4 more Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-H1 $549M $195M $1.1B $55M report ↗ 2023-H1 $390M $133M $1.1B $20M report ↗ 2022-H1 $346M $181M $1.2B $147M report ↗ 2021-H1 $300M $161M $1.7B $182M report ↗
Annual history (5 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $1.9B $387M $2.6B — report ↗
View 4 more years Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $1.3B $373M $1.4B $13M report ↗ 2023-FY $878M $315M $1.5B $145M report ↗ 2022-FY $678M $428M $1.3B $325M report ↗ 2021-FY $662M $384M $1.4B $487M report ↗